SITAZIT M 50/500 10S

About

SITAZIT M 50/500 is an oral antidiabetic medication combining Sitagliptin (50mg) and Metformin (500mg), used for the treatment of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to control blood glucose by increasing the levels of active incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, works primarily by reducing glucose production in the liver, decreasing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues.

This combination therapy provides a comprehensive approach to glycemic control, addressing both impaired insulin secretion and insulin resistance, which are key pathophysiological defects in type 2 diabetes. SITAZIT M 50/500 is typically prescribed as an adjunct to diet and exercise for adults with type 2 diabetes who have not achieved adequate glycemic control with monotherapy or who are already being treated with both Sitagliptin and Metformin as separate tablets.

Uses

• Management of type 2 diabetes mellitus
• Improvement of blood sugar levels
• Reduction of HbA1c
• Used as an adjunct to diet and exercise

Directions For Use

Take one tablet orally twice daily with meals, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Dual mechanism for effective glucose lowering
• Targets multiple aspects of diabetes pathophysiology
• Helps achieve target HbA1c levels
• Generally low risk of hypoglycemia
• May contribute to modest weight stabilization
• Improves overall glycemic control

Side Effects

• Nausea
• Diarrhea
• Abdominal discomfort
• Vomiting
• Headache
• Upper respiratory tract infection
• Sore throat
• Hypoglycemia (when used with insulin or sulfonylureas)
• Pancreatitis (rare)
• Lactic acidosis (rare, Metformin)
• Joint pain
• Metallic taste

Safety Measures

• Alcohol - Avoid excessive alcohol intake as it can significantly increase the risk of lactic acidosis, a rare but serious side effect of Metformin.
• Pregnancy - Consult a doctor. Generally not recommended during pregnancy due to limited safety data and potential risks to the fetus.
• Breastfeeding - Consult a doctor. Metformin is excreted into breast milk; Sitagliptin excretion is not fully established.
• Liver - Contraindicated in severe hepatic impairment due to the increased risk of Metformin-associated lactic acidosis. Liver function should be monitored.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Dose adjustment is necessary for moderate impairment.
• Lung - Generally safe for lung conditions. However, conditions causing hypoxemia (e.g., severe respiratory failure) may increase the risk of lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.